Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Lewis

Nurse Practitioner, Pediatrics Raleigh, NC Nurse Practitioner

NPI 1174776157 CMS profile 10468302

1540 Sunday Dr, Raleigh, NC 27607

Open in the dashboard

General payments

$10,311

288 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Lewis of Raleigh, NC is reported in the CMS Open Payments database as having received $10,311 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,923 69
2024 General $2,532 72
2023 General $1,977 64
2022 General $2,559 73
2021 General $321 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Lewis
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Carrie Lewis were reported at $2,923. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Carrie Lewis Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $321 $60 $23–$142 $132
2022 $2,559 $72 $27–$161 $149
2023 $1,977 $89 $35–$185 $160
2024 $2,532 $93 $34–$199 $164
2025 $2,923 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LivaNova USA, Inc. $3,410 12 payments
  2. UCB, Inc. $2,210 88 payments
  3. AbbVie, Inc. $483 22 payments
  4. Neurelis, Inc. $412 19 payments
  5. CSL Behring $400 1 payment
  6. Eisai Inc. $278 16 payments
  7. Jazz Pharmaceuticals Inc. $234 10 payments
  8. Sumitomo Pharma America, Inc. $225 13 payments
  9. Sanofi Pasteur Inc. $216 2 payments
  10. Merz Pharmaceuticals, LLC $214 6 payments
  11. Other $2,229 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,403 280 payments
  2. Travel and Lodging $2,508 7 payments
  3. Education $400 1 payment
Products named General payments · program years 2021–2025
  1. VNS Therapy Neurology $2,203 8 payments
  2. VNS Therapy Cardiology/Vascular Diseases $1,207 4 payments
  3. Briviact $890 37 payments
  4. Fintepla $848 33 payments
  5. Nayzilam $454 17 payments
  6. QULIPTA $426 19 payments
  7. VALTOCO $412 19 payments
  8. Kcentra $400 1 payment
  9. APTIOM $302 19 payments
  10. UBRELVY $267 15 payments
  11. Other $2,906 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record